Armistice Capital LLC Purchases 532,000 Shares of Grifols, S.A. $GRFS

Armistice Capital LLC lifted its position in shares of Grifols, S.A. (NASDAQ:GRFS) by 23.8% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 2,768,000 shares of the biotechnology company’s stock after acquiring an additional 532,000 shares during the quarter. Armistice Capital LLC owned approximately 0.40% of Grifols worth $25,881,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently made changes to their positions in GRFS. Bank of Montreal Can raised its position in shares of Grifols by 3,205.1% during the third quarter. Bank of Montreal Can now owns 3,013,723 shares of the biotechnology company’s stock worth $30,017,000 after acquiring an additional 2,922,540 shares during the last quarter. Arrowstreet Capital Limited Partnership grew its stake in shares of Grifols by 383.7% during the third quarter. Arrowstreet Capital Limited Partnership now owns 2,800,645 shares of the biotechnology company’s stock worth $27,894,000 after purchasing an additional 2,221,633 shares during the period. Norges Bank acquired a new stake in shares of Grifols during the fourth quarter worth $18,139,000. Brandes Investment Partners LP grew its stake in shares of Grifols by 6.3% during the fourth quarter. Brandes Investment Partners LP now owns 30,954,223 shares of the biotechnology company’s stock worth $289,422,000 after purchasing an additional 1,838,727 shares during the period. Finally, Barclays PLC grew its stake in shares of Grifols by 132.6% during the fourth quarter. Barclays PLC now owns 2,434,636 shares of the biotechnology company’s stock worth $22,764,000 after purchasing an additional 1,387,783 shares during the period.

Grifols Stock Performance

Shares of Grifols stock opened at $7.46 on Thursday. The firm has a market cap of $5.08 billion, a price-to-earnings ratio of 39.26, a price-to-earnings-growth ratio of 0.29 and a beta of 0.65. The stock’s 50-day moving average is $7.97 and its 200-day moving average is $8.54. Grifols, S.A. has a one year low of $7.26 and a one year high of $11.14. The company has a debt-to-equity ratio of 1.16, a current ratio of 2.47 and a quick ratio of 0.85.

Grifols (NASDAQ:GRFS) last issued its quarterly earnings results on Saturday, February 14th. The biotechnology company reported $0.38 EPS for the quarter. Grifols had a return on equity of 6.21% and a net margin of 5.54%.The company had revenue of $2.32 billion for the quarter. Equities analysts predict that Grifols, S.A. will post 1.06 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research analysts have issued reports on the company. Zacks Research cut Grifols from a “hold” rating to a “strong sell” rating in a research note on Friday, May 8th. Weiss Ratings raised Grifols from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Friday, May 8th. Finally, Wall Street Zen cut Grifols from a “buy” rating to a “hold” rating in a research note on Monday, May 18th. Three investment analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Reduce” and a consensus price target of $10.00.

Grifols Profile

Grifols, Inc (NASDAQ: GRFS) is a global healthcare company specializing in the development, manufacture and marketing of plasma-derived medicines, diagnostic systems and hospital supplies. With a core focus on immunotherapy and transfusion medicine, the company harnesses human plasma proteins to create therapies that treat a wide range of bleeding disorders, immunodeficiencies and neurological conditions. Grifols also supplies reagents and diagnostic instruments for transfusion centers and clinical laboratories, alongside intravenous solutions and medical devices for hospital use.

The company operates three main business units.